Contract research organization ALMEDIS
E-mail:
info@almedis.ru
Tel: +7 495 937 43 18
Fax: +7 495 937 43 19
Address: 5, Ulitsa Malaya Pirogovskaya, office 22, 119435 Moscow, Russia

RUS ENG
About Us
Our Services
Quality
Contact Us
News
Links
Career

ALMEDIS is an independent contract research organization (CRO) with operations all over Russia

ALMEDIS provides comprehensive range of services in international and local clinical trials, observational studies, data management, biostatistics, medical writing and training programs.

Our CRO is committed to meeting the needs and expectations of our clients by providing professional and superior quality service, with integrity, reliability and strong client focus.

ALMEDIS is a member of the Association of Clinical Trial Organizations (ACTO).

    ALMEDIS is an Effective Resource for:
  • International pharmaceutical companies
  • International contract research organizations (CROs)
  • Pharmaceutical and biotech companies launching their clinical research activities in Russia
  • Scientific research organizations

Since 2007 ALMEDIS team has successfully managed more than 100 projects, including international and local Phase II - IV clinical trials and observational studies.

This year ALMEDIS marks the decade of successful collaboration with a leading international Life Sciences technology provider Ennov

          Latest News:
  • ALMEDIS received the approval of the Ministry of Health for conduction in Russia of the international clinical trial, phase IV, for prevention of recurrent thromboembolic complications during pregnancy (Highlow). This study is initiated by Academic Medical Center, the Netherlands, and conducted in France, Ireland, Belgium, Norway, USA and Canada. The information about the study can be found on its webpage.
  • Clinical study report has been prepared and approved by the sponsor for the international multicentre clinical study of bioequivalence in patients with advanced prostate cancer.
  • ALMEDIS received the approval of the Interdisciplinary Ethics Committee for conduction of a study evaluating the effect of the biologically active supplement (probiotic Lactobacillus reuteri) on formation of intestinal microbiota in children born by cesarean section.
  • ALMEDIS prepared the article based on results of a clinical study of the efficacy, safety and tolerability of the drug for colon cleansing before colonoscopy.

 




ALMEDIS is solely responsible for this site content. This information is intended for use by our customers and clinical research specialists.
© 2006-2018 ALMEDIS All rights reserved 

Privacy Policy